Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 52

1.

ACO: Time to move from the description of different phenotypes to the treatable traits.

Toledo-Pons N, van Boven JFM, Román-Rodríguez M, Pérez N, Valera Felices JL, Soriano JB, Cosío BG.

PLoS One. 2019 Jan 24;14(1):e0210915. doi: 10.1371/journal.pone.0210915. eCollection 2019.

2.

Making sense of cost-effectiveness analyses in respiratory medicine: a practical guide for non-health economists.

van Boven JFM, van de Hei SJ, Sadatsafavi M.

Eur Respir J. 2018 Dec 21. pii: 1801816. doi: 10.1183/13993003.01816-2018. [Epub ahead of print] No abstract available.

PMID:
30578398
3.

High COPD prevalence at high altitude: does household air pollution play a role?

Brakema EA, Tabyshova A, Kasteleyn MJ, Molendijk E, van der Kleij RMJJ, van Boven JFM, Emilov B, Akmatalieva M, Mademilov M, Numans ME, Williams S, Sooronbaev T, Chavannes NH.

Eur Respir J. 2019 Feb 7;53(2). pii: 1801193. doi: 10.1183/13993003.01193-2018. Print 2019 Feb.

4.

Real-world effectiveness evaluation of budesonide/formoterol Spiromax for the management of asthma and chronic obstructive pulmonary disease in the UK.

Voorham J, Roche N, Benhaddi H, van der Tol M, Carter V, van Boven JFM, Bjermer L, Miravitlles M, Price DB.

BMJ Open. 2018 Oct 27;8(10):e022051. doi: 10.1136/bmjopen-2018-022051. Erratum in: BMJ Open. 2018 Dec 9;8(12):e022051corr1.

5.

Does Changing Inhaler Device Impact Real-Life Asthma Outcomes? Clinical and Economic Evaluation.

Rhee CK, van Boven JFM, Yau Ming SW, Park HY, Kim DK, Park HS, Ling JZJ, Yoo KH, Price DB.

J Allergy Clin Immunol Pract. 2018 Oct 5. pii: S2213-2198(18)30604-4. doi: 10.1016/j.jaip.2018.09.027. [Epub ahead of print]

PMID:
30292924
6.

Development of the International Severe Asthma Registry (ISAR): A Modified Delphi Study.

Bulathsinhala L, Eleangovan N, Heaney LG, Menzies-Gow A, Gibson PG, Peters M, Hew M, van Boven JFM, Lehtimäki L, van Ganse E, Belhassen M, Harvey ES, Perez de Llano L, Maitland-van der Zee AH, Papadopoulos NG, FitzGerald JM, Porsbjerg C, Canonica GW, Backer V, Rhee CK, Verhamme KMC, Buhl R, Cosio BG, Carter V, Price C, Le T, Stagno d'Alcontres M, Gopalan G, Tran TN, Price D.

J Allergy Clin Immunol Pract. 2019 Feb;7(2):578-588.e2. doi: 10.1016/j.jaip.2018.08.016. Epub 2018 Sep 1.

PMID:
30179741
7.

Personalising adherence-enhancing interventions using a smart inhaler in patients with COPD: an exploratory cost-effectiveness analysis.

van Boven JFM, Cushen B, Sulaiman I, Greene G, MacHale E, Mokoka MC, Doyle F, Reilly RB, Bennett K, Costello RW.

NPJ Prim Care Respir Med. 2018 Jun 27;28(1):24. doi: 10.1038/s41533-018-0092-8.

8.

Electric scooters: batteries in the battle against ambient air pollution?

van Boven JFM, An PL, Kirenga BJ, Chavannes NH.

Lancet Planet Health. 2017 Aug;1(5):e168-e169. doi: 10.1016/S2542-5196(17)30079-7. Epub 2017 Aug 4. No abstract available.

9.

Cost-Effectiveness of Biological Asthma Treatments: A Systematic Review and Recommendations for Future Economic Evaluations.

McQueen RB, Sheehan DN, Whittington MD, van Boven JFM, Campbell JD.

Pharmacoeconomics. 2018 Aug;36(8):957-971. doi: 10.1007/s40273-018-0658-x. Review.

PMID:
29736895
10.

HbA1c response after insulin initiation in patients with type 2 diabetes mellitus in real life practice: Identifying distinct subgroups.

Sidorenkov G, van Boven JFM, Hoekstra T, Nijpels G, Hoogenberg K, Denig P.

Diabetes Obes Metab. 2018 Aug;20(8):1957-1964. doi: 10.1111/dom.13332. Epub 2018 May 24.

11.

Availability, use, and affordability of medicines in urban China under universal health coverage: an empirical study in Hangzhou and Baoji.

Huang Y, Jiang Y, Zhang L, Mao W, van Boven JFM, Postma MJ, Chen W.

BMC Health Serv Res. 2018 Mar 27;18(1):218. doi: 10.1186/s12913-018-2993-1.

12.

The Clinical Impact of Different Adherence Behaviors in Patients with Severe Chronic Obstructive Pulmonary Disease.

Cushen B, Sulaiman I, Greene G, MacHale E, Mokoka M, Reilly RB, Bennett K, Doyle F, van Boven JFM, Costello RW.

Am J Respir Crit Care Med. 2018 Jun 15;197(12):1630-1633. doi: 10.1164/rccm.201712-2469LE. No abstract available.

PMID:
29351380
13.

Addressing the Impact and Unmet Needs of Nonadherence in Asthma and Chronic Obstructive Pulmonary Disease: Where Do We Go From Here?

Dekhuijzen R, Lavorini F, Usmani OS, van Boven JFM.

J Allergy Clin Immunol Pract. 2018 May - Jun;6(3):785-793. doi: 10.1016/j.jaip.2017.11.027. Epub 2018 Jan 12.

14.

Indacaterol/glycopyrronium is cost-effective compared to salmeterol/fluticasone in COPD: FLAME-based modelling in a Swedish population.

Bjermer L, van Boven JFM, Costa-Scharplatz M, Keininger DL, Gutzwiller FS, Lisspers K, Mahon R, Olsson P, Roche N.

Respir Res. 2017 Dec 11;18(1):206. doi: 10.1186/s12931-017-0688-5.

15.

Asthma Cost-Effectiveness Analyses: Are We Using the Recommended Outcomes in Estimating Value?

Kim CH, Dilokthornsakul P, Campbell JD, van Boven JFM.

J Allergy Clin Immunol Pract. 2018 Mar - Apr;6(2):619-632. doi: 10.1016/j.jaip.2017.07.028. Epub 2017 Sep 28.

PMID:
28967548
16.

Costly comorbidities of COPD: the ignored side of the coin?

van Boven JFM.

Eur Respir J. 2017 Jul 27;50(1). pii: 1700917. doi: 10.1183/13993003.00917-2017. Print 2017 Jul. No abstract available.

17.
18.

Urging Europe to put non-adherence to inhaled respiratory medication higher on the policy agenda: a report from the First European Congress on Adherence to Therapy.

van Boven JFM, Lavorini F, Dekhuijzen PNR, Blasi F, Price DB, Viegi G.

Eur Respir J. 2017 May 19;49(5). pii: 1700076. doi: 10.1183/13993003.00076-2017. Print 2017 May. No abstract available.

19.

Does co-payment for inhaler devices affect therapy adherence and disease outcomes? A historical, matched cohort study.

Voorham J, Vrijens B, van Boven JF, Ryan D, Miravitlles M, Law LM, Price DB.

Pragmat Obs Res. 2017 Apr 18;8:31-41. doi: 10.2147/POR.S132658. eCollection 2017.

20.

Effectiveness and success factors of educational inhaler technique interventions in asthma & COPD patients: a systematic review.

Klijn SL, Hiligsmann M, Evers SMAA, Román-Rodríguez M, van der Molen T, van Boven JFM.

NPJ Prim Care Respir Med. 2017 Apr 13;27(1):24. doi: 10.1038/s41533-017-0022-1. Review.

21.

Associations between chronic comorbidity and exacerbation risk in primary care patients with COPD.

Westerik JA, Metting EI, van Boven JF, Tiersma W, Kocks JW, Schermer TR.

Respir Res. 2017 Feb 6;18(1):31. doi: 10.1186/s12931-017-0512-2.

22.

Clinical characteristics, treatment patterns, and socio-economic burden of COPD in Bulgaria.

Kamusheva M, Dimitrova M, van Boven JF, Postma MJ, van der Molen T, Kocks JW, Mitov K, Doneva M, Petrova D, Georgiev O, Petkova V, Petrova G.

J Med Econ. 2017 May;20(5):503-509. doi: 10.1080/13696998.2017.1279620. Epub 2017 Jan 23.

PMID:
28058859
23.

Cost comparison of asthma treatments in 12-week study: caution about matching and short observational follow-up.

Price DB, van Boven JF, Law LM, Cifra A, McQueen RB.

Multidiscip Respir Med. 2016 Nov 2;11:39. eCollection 2016.

24.

Optimizing identification and management of COPD patients - reviewing the role of the community pharmacist.

van der Molen T, van Boven JF, Maguire T, Goyal P, Altman P.

Br J Clin Pharmacol. 2017 Jan;83(1):192-201. doi: 10.1111/bcp.13087. Epub 2016 Nov 2. Review.

25.
26.

COPD case finding: effective, but also cost-effective?

van Boven JF, McQueen RB, Price DB.

Lancet Respir Med. 2016 Oct;4(10):e49. doi: 10.1016/S2213-2600(16)30266-1. No abstract available.

PMID:
27707463
27.

Cost-effectiveness and budget impact of the fixed-dose dual bronchodilator combination tiotropium-olodaterol for patients with COPD in the Netherlands.

van Boven JF, Kocks JW, Postma MJ.

Int J Chron Obstruct Pulmon Dis. 2016 Sep 19;11:2191-2201. eCollection 2016.

28.

Factors associated with inhaled corticosteroids prescription in primary care patients with COPD: A cross-sectional study in the Balearic Islands (Spain).

Román-Rodríguez M, van Boven JF, Vargas F, Contreras CC, Lamelas G, Gestoso S, Góngora M, Corredor M, Esteva M.

Eur J Gen Pract. 2016 Dec;22(4):232-239. doi: 10.1080/13814788.2016.1212011. Epub 2016 Sep 6.

PMID:
27597172
29.

Systematic Review and Quality Appraisal of Cost-Effectiveness Analyses of Pharmacologic Maintenance Treatment for Chronic Obstructive Pulmonary Disease: Methodological Considerations and Recommendations.

van der Schans S, Goossens LMA, Boland MRS, Kocks JWH, Postma MJ, van Boven JFM, Rutten-van Mölken MPMH.

Pharmacoeconomics. 2017 Jan;35(1):43-63. doi: 10.1007/s40273-016-0448-2. Review.

30.

Enhancing Respiratory Medication Adherence: The Role of Health Care Professionals and Cost-Effectiveness Considerations.

van Boven JF, Ryan D, Eakin MN, Canonica GW, Barot A, Foster JM; Respiratory Effectiveness Group.

J Allergy Clin Immunol Pract. 2016 Sep-Oct;4(5):835-46. doi: 10.1016/j.jaip.2016.03.007. Review.

31.

What We Mean When We Talk About Adherence in Respiratory Medicine.

Vrijens B, Dima AL, Van Ganse E, van Boven JF, Eakin MN, Foster JM, de Bruin M, Chisholm A, Price D.

J Allergy Clin Immunol Pract. 2016 Sep-Oct;4(5):802-12. doi: 10.1016/j.jaip.2016.05.019. Review.

32.

Comorbidome, Pattern, and Impact of Asthma-COPD Overlap Syndrome in Real Life.

van Boven JF, Román-Rodríguez M, Palmer JF, Toledo-Pons N, Cosío BG, Soriano JB.

Chest. 2016 Apr;149(4):1011-20. doi: 10.1016/j.chest.2015.12.002. Epub 2015 Dec 14.

PMID:
26836892
33.

Investigating the association between medication adherence and health-related quality of life in COPD: Methodological challenges when using a proxy measure of adherence.

Boland MR, van Boven JF, Kruis AL, Chavannes NH, van der Molen T, Goossens LM, Rutten-van Mölken MP.

Respir Med. 2016 Jan;110:34-45. doi: 10.1016/j.rmed.2015.11.008. Epub 2015 Nov 23.

34.

Effects of targeting disease and medication management interventions towards patients with COPD.

van Boven JF, Stuurman-Bieze AG, Hiddink EG, Postma MJ.

Curr Med Res Opin. 2016;32(2):229-39. doi: 10.1185/03007995.2015.1110129. Epub 2015 Nov 17.

PMID:
26479017
35.

Predictors of cost-effectiveness of selected COPD treatments in primary care: UNLOCK study protocol.

van Boven JF, Román-Rodríguez M, Kocks JW, Soriano JB, Postma MJ, van der Molen T.

NPJ Prim Care Respir Med. 2015 Aug 6;25:15051. doi: 10.1038/npjpcrm.2015.51. No abstract available.

36.

Towards tailored and targeted adherence assessment to optimise asthma management.

van Boven JF, Trappenburg JC, van der Molen T, Chavannes NH.

NPJ Prim Care Respir Med. 2015 Jul 16;25:15046. doi: 10.1038/npjpcrm.2015.46.

37.

Higher Adherence During Reimbursement of Pharmacological Smoking Cessation Treatments.

van Boven JF, Vemer P.

Nicotine Tob Res. 2016 Jan;18(1):56-63. doi: 10.1093/ntr/ntv064. Epub 2015 Mar 16.

PMID:
25782457
38.

Mapping the clinical chronic obstructive pulmonary disease questionnaire onto generic preference-based EQ-5D values.

Boland MR, van Boven JF, Kocks JW, van der Molen T, Goossens LM, Chavannes NH, Rutten-van Mölken MP.

Value Health. 2015 Mar;18(2):299-307. doi: 10.1016/j.jval.2014.11.006. Epub 2015 Feb 2.

39.

Sustainable Policy: Higher Medication Use & Adherence During Reimbursement of Pharmacologic Smoking Cessation Treatments.

Van Boven JF, Vemer P.

Value Health. 2014 Nov;17(7):A603. doi: 10.1016/j.jval.2014.08.2094. Epub 2014 Oct 26. No abstract available.

40.

Impact of multiple-dose versus single-dose inhaler devices on COPD patients' persistence with long-acting β₂-agonists: a dispensing database analysis.

van Boven JF, van Raaij JJ, van der Galiën R, Postma MJ, van der Molen T, Dekhuijzen PN, Vegter S.

NPJ Prim Care Respir Med. 2014 Oct 2;24:14069. doi: 10.1038/npjpcrm.2014.69.

41.

[Optimizing pharmacotherapy in patients with COPD by community-pharmacists: a cost-effectiveness analysis].

van Boven JF, Tommelein E, Boussery K, Mehuys E, Vegter S, Brusselle GG, Rutten-van Mölken MP, Postma MJ.

J Pharm Belg. 2014 Sep;(3):15-6. French. No abstract available.

PMID:
25226758
42.

Medication monitoring and optimization: a targeted pharmacist program for effective and cost-effective improvement of chronic therapy adherence.

van Boven JF, Stuurman-Bieze AG, Hiddink EG, Postma MJ, Vegter S.

J Manag Care Spec Pharm. 2014 Aug;20(8):786-92.

43.

Improving adherence to lipid-lowering therapy in a community pharmacy intervention program: a cost-effectiveness analysis.

Vegter S, Oosterhof P, van Boven JF, Stuurman-Bieze AG, Hiddink EG, Postma MJ.

J Manag Care Spec Pharm. 2014 Jul;20(7):722-32.

44.

Improving inhaler adherence in patients with chronic obstructive pulmonary disease: a cost-effectiveness analysis.

van Boven JF, Tommelein E, Boussery K, Mehuys E, Vegter S, Brusselle GG, Rutten-van Mölken MP, Postma MJ.

Respir Res. 2014 Jun 14;15:66. doi: 10.1186/1465-9921-15-66.

45.

Proactive pharmaceutical care interventions decrease patients' nonadherence to osteoporosis medication.

Stuurman-Bieze AG, Hiddink EG, van Boven JF, Vegter S.

Osteoporos Int. 2014 Jun;25(6):1807-12. doi: 10.1007/s00198-014-2659-8. Epub 2014 Feb 26.

PMID:
24570297
46.

Economic evaluation of ropinirole prolonged release for treatment of Parkinson's disease in the Netherlands.

van Boven JF, Novak A, Driessen MT, Boersma C, Boomsma MM, Postma MJ.

Drugs Aging. 2014 Mar;31(3):193-201. doi: 10.1007/s40266-013-0150-4.

PMID:
24399580
47.

Proactive pharmaceutical care interventions improve patients' adherence to lipid-lowering medication.

Stuurman-Bieze AG, Hiddink EG, van Boven JF, Vegter S.

Ann Pharmacother. 2013 Nov;47(11):1448-56. doi: 10.1177/1060028013501146. Epub 2013 Nov 18.

PMID:
24259595
48.

Clinical and economic impact of non-adherence in COPD: a systematic review.

van Boven JF, Chavannes NH, van der Molen T, Rutten-van Mölken MP, Postma MJ, Vegter S.

Respir Med. 2014 Jan;108(1):103-13. doi: 10.1016/j.rmed.2013.08.044. Epub 2013 Sep 11. Review.

49.

The pharmacists' potential to provide targets for interventions to optimize pharmacotherapy in patients with asthma.

van Boven JF, Hiddink EG, Stuurman-Bieze AG, Schuiling-Veninga CC, Postma MJ, Vegter S.

Int J Clin Pharm. 2013 Dec;35(6):1075-82. doi: 10.1007/s11096-013-9829-1. Epub 2013 Jul 26.

PMID:
23888347
50.

COPD in the working age population: the economic impact on both patients and government.

van Boven JF, Vegter S, van der Molen T, Postma MJ.

COPD. 2013 Dec;10(6):629-39. doi: 10.3109/15412555.2013.813446. Epub 2013 Jul 11.

PMID:
23845002

Supplemental Content

Loading ...
Support Center